Sarda Proteins Faces Ownership Change Amid Regulatory Hurdles

The open offer by Onix Renewable Limited for Sarda Proteins Ltd has been announced, with the acquirer offering ₹115 per share for 17,30,400 shares, representing 19.28% of the company. The offer runs from June 11 to June 24, 2026.

Reader Takeaway: Exit opportunity at ₹115 per share; cautious outlook due to regulatory scrutiny and past compliance issues.

What Just Happened

Onix Renewable Limited, along with its Persons Acting in Concert (PACs), has triggered a mandatory open offer for Sarda Proteins Ltd. This action follows the conversion of 72,50,000 warrants into equity shares. The offer is for 17,30,400 shares, constituting 19.28% of the company's emerging voting share capital, at a price of ₹115.00 per share, payable in cash.

Why This Matters

The open offer provides a potential exit route for existing public shareholders of Sarda Proteins at a price of ₹115.00 per share. However, the company is currently under Stage-4 of the Graded Surveillance Measure (GSM) framework on the BSE, which limits trading activity and liquidity. Additionally, Sarda Proteins faces a stock suspension on the Calcutta Stock Exchange (CSE) due to non-compliance, signaling potential governance risks.

The Backstory

Sarda Proteins is already listed on the BSE and has been under regulatory surveillance due to its GSM Stage-4 placement. The company also has a history of non-compliance issues, which led to its suspension on the CSE. The open offer comes after the conversion of warrants, which effectively changed the shareholding structure and triggered the mandatory takeover requirement.

What Changes Now

Onix Renewable Limited intends to continue Sarda Proteins' current business but may also explore diversification. The change in control and management introduces a new strategic direction. However, existing shareholders must weigh the offer price against the company's regulatory challenges and past compliance record. The acquirer will need to address the public shareholding requirements to meet the minimum 25% threshold.

Risks to Watch

The primary risks for investors include the ongoing GSM Stage-4 placement, which restricts trading and requires additional deposit requirements for buyers. Past SEBI/LODR non-compliance points to potential future governance risks. Furthermore, ensuring listing compliance regarding public shareholding may necessitate future dilution or divestment by the new management.

Peer Comparison

Information on Sarda Proteins' direct peers in the protein or related sectors is not directly available in the filing, but its current regulatory status (GSM Stage-4 and CSE suspension) is a significant operational constraint not typically seen in healthy, actively traded companies.

Context Metrics (Time-bound)

Acquirer's Net Worth: ₹789.51 crore as of September 30, 2025.
Maximum Offer Consideration: ₹19.90 crore for full acceptance.
Escrow Amount: ₹4.97 crore for the open offer.
Offer Dates: June 11, 2026, to June 24, 2026.

What to Track Next

Investors should closely monitor the response to the open offer and any future announcements regarding the new management's business plans. Crucially, tracking the company's efforts to resolve its regulatory issues, including the GSM status and CSE suspension, will be essential for assessing its long-term prospects.